Finoriq

Finoriq research workspace

Adaptive Biotechnologies Corp (ADPT) Institutional Holdings & 13F Ownership

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine. Review ADPT institutional holders, 13F ownership, and position changes on Finoriq.

Company Snapshot

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Company
Adaptive Biotechnologies Corp (ADPT)
Ticker
ADPT
Market Cap
$3.5B
Latest Price
$21.85
Industry
Biotech & Pharma

Open insider transactions

Adaptive Biotechnologies Corp (ADPT) Top Institutional Holders

Top current 13F holders indexed for Adaptive Biotechnologies Corp (ADPT). Latest period 2026-03-31.

RankInvestorValuePortfolioFiling
1Viking Global InvestorsCIK 0001103804$416.3M1.2%Filing2026-05-15
2Polen Capital ManagementCIK 0001034524$1.6M0.01%Filing2026-05-14
3Joel GreenblattCIK 0001510387$1.3M0.0%Filing2026-05-15
4Ray DalioCIK 0001350694$1.2M0.01%Filing2026-05-15

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.